At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 720 enrolled
Drug / intervention
Prasugrel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Comparison of Platelet Inhibition Following Prasugrel or Clopidogrel Administration in Asian Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
In Brief
A Phase 3 clinical trial evaluating Prasugrel and Clopidogrel for Acute Coronary Syndrome. Completed, enrolled 720 participants across 19 sites in 4 countries.
Detailed Summary
The study will compare the safety and efficacy of prasugrel, administered at different doses with clopidogrel in the treatment of Asian participants with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Coronary Syndrome
CountriesChina, South Korea, Taiwan, Thailand
CollaboratorsDaiichi Sankyo Co., Ltd.
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2009
Enrollment StartFeb 2009
Primary CompletionJun 2010
TodayJul 2026
First PostedJan 28, 2009
Enrollment StartFeb 1, 2009
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.4 years ago
Interventions
Prasugreldrug
Oral, daily, 90 days
Clopidogreldrug
Oral, daily, 90 days